Table 2.
Serum testosterone on each days after switching to lueprolide
| Day 0 | Day 1 | Day 2 | Day 5 | Day 7 | ||
|---|---|---|---|---|---|---|
| ECLIA | Total (n = 39) | 7.5 ± 5.8 | 19.7 ± 27.5 | 17.4 ± 18.2 | 7.0 ± 4.8 | 6.7 ± 4.6 |
| Surge (-) | ||||||
| Total (n = 36) | 7.6 ± 6.0 | 13.5 ± 10.6 | 14.3 ± 11.2 | 7.1 ± 4.8 | 6.8 ± 4.7 | |
| 3 m group (n = 9) | 8.2 ± 6.8 | 11.9 ± 10.6 | 11.9 ± 11.4 | 7.9 ± 5.7 | 6.9 ± 5.0 | |
| 2 m group (n = 9) | 6.0 ± 5.6 | 10.6 ± 11.9 | 9.0 ± 8.0 | 6.0 ± 5.7 | 6.3 ± 5.6 | |
| 1 m group (n = 19) | 8.2 ± 5.9 | 15.7 ± 5.9 | 18.2 ± 11.5 | 7.2 ± 4.0 | 7.1 ± 4.1 | |
| Surge (+) | ||||||
| No.10 (3 m) | 10.0 | 161.0 | 88.0 | 3.0 | 3.0 | |
| No.18 (2 m) | 3.0 | 63.0 | 69.0 | 3.0 | 3.0 | |
| No.30 (1 m) | 3.0 | 59.0 | 5.0 | 12.0 | 9.0 | |
| LC-MS/MS | Total (n = 36) | 8.6 ± 4.4 | 24.1 ± 25.3 | 22.6 ± 20.6 | 8.6 ± 2.7 | 8.0 ± 3.0 |
| Surge (-) | ||||||
| Total (n = 33) | 7.9 ± 3.0 | 17.9 ± 10.3 | 19.1 ± 13.4 | 8.4 ± 2.6 | 7.6 ± 2.6 | |
| 3 m group (n = 9) | 8.6 ± 3.3 | 15.7 ± 12.3 | 15.4 ± 11.5 | 8.4 ± 3.4 | 8.0 ± 3.1 | |
| 2 m group (n = 8) | 6.4 ± 2.6 | 14.9 ± 12.5 | 11.1 ± 11.1 | 6.8 ± 2.7 | 6.6 ± 3.2 | |
| 1 m group (n = 16) | 8.3 ± 2.9 | 20.8 ± 7.4 | 24.4 ± 13.7 | 9.2 ± 1.6 | 7.9 ± 1.9 | |
| Surge (+) | ||||||
| No.10 (3 m) | 28.0 | 142.0 | 93.0 | 12.0 | 16.0 | |
| No.18 (2 m) | 12.0 | 72.0 | 80.0 | 9.0 | 12.0 | |
| No.30 (1 m) | 7.0 | 63.0 | 7.0 | 12.0 | 9.0 |
Data are presented as means ± SD unless indicated otherwise
ECLIA electrochemiluminescence Immunoassay; LC-MS/MS liquid chromatography-tandem mass spectrometry; surge (-) means a testosterone surge of down to 50 ng/dl was observed, surge (+) means a testosterone surge of up to 50 ng/dl was observed